SRX Global Inc. SRXH
0.89 USD -0.04 (-4.78%)
Regular-session close
0.91 +0.03 +2.95%
Pre-market · Nov 18, 7:19 AM ET
0.8746 Day range 0.9585
0.71 52-week range 42.60
- YTD
- -93.52%
- 1 year
- -94.38%
- Market cap
- 17.90M
- EPS (ttm)
- 62.19
- Shares out
- 858.60M
- P/E ratio
- 0.01
- YTD return
- -93.52%
- 1-year return
- -94.38%
- Volume
- 322.27K
- Avg volume
- 592.86K
- Open
- 0.94575
- Previous close
- 0.9315
- Day's range
- 0.8746 – 0.9585
- 52-week range
- 0.71 – 42.60
5D +0.0710 (+7.99%)
Key statistics
- 50-day average
- 7.12
- 200-day average
- 12.23
- Price / book
- 36.79
- Short % of float
- 0.06%
Fundamental scorecard
6 of 25 checks passed on SRXH’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
SRXH Revenue — quarterly 3.39M
SRXH Net income — quarterly -4.14M
SRXH EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 14, 2026 | Mar 31, 2026 | -0.26 | -1.20 | -0.94 | -361.54% |
| Feb 13, 2026 | Dec 31, 2025 | — | -0.17 | — | — |
| Nov 10, 2025 | Sep 30, 2025 | — | -24.00 | — | — |
| Sep 30, 2025 | Jun 30, 2025 | -4.84 | -0.74 | +4.10 | +84.71% |
| May 15, 2025 | Mar 31, 2025 | -2.21 | -0.37 | +1.84 | +83.26% |
| Mar 27, 2025 | Dec 31, 2024 | -2.20 | -30.00 | -27.80 | -1,264.55% |
About SRX Global Inc.
SRX Global Inc. designs and develops an artificial intelligence (AI)-based platform to enhance decision making, operations, and risk management. The company is based in Tampa, Florida.
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Country
- United States
- Website
- srxglobalinc.com
News
SRX Global Says As Of October 30, 2026, The Company Has ~$34M In Aggregate Cash, Cash Equivalents, Restricted Cash And Short-Term U.S. Treasury Bills; The Company Does Not Have Any Exposure To Cryptocurrency As Of Today
SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics
Your note
Sign in to keep a note on SRXH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CONACHER LIONEL F | Director | Sale | Dec 22, 2024 | 36,597 |
| CONWAY SIMON ALEXANDER MALCOLM | Director | Stock Award(Grant) | Dec 2, 2025 | 1,039,580 |
| CUNNINGHAM KENT | Chief Executive Officer | Stock Award(Grant) | Dec 2, 2025 | 0 |
| WHITE DAVID ALLAN | Director | Stock Award(Grant) | Aug 24, 2025 | 731,406 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jane Street Group, LLC | 0.00% | 9,921 | 13.51K | Mar 30, 2026 |
| Geode Capital Management, LLC | 0.00% | 4,125 | 5.62K | Mar 30, 2026 |
| Two Sigma Securities, LLC | 0.00% | 3,254 | 4.43K | Mar 30, 2026 |
| Scotia Capital Inc. | 0.00% | 1,802 | 2.45K | Mar 30, 2026 |
| UBS Group AG | 0.00% | 1,429 | 1.95K | Mar 30, 2026 |
| Xtx Topco Ltd | 0.00% | 1,222 | 1.66K | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.00% | 3,828 | 5.21K | May 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 0.00% | 195 | 265 | May 30, 2026 |
